新型氯法齐明制剂及给药策略在儿童耐利福平结核中的药代动力学与安全性
本研究评估了50mg氯法齐明片剂按修订的每日一次体重分层给药方案在<18岁、<30kg的MDR/RR-TB患儿中的暴露与安全性。12例患儿的中位预测稳态周AUC为106 mg·h/L,在成人目标111.79 mg·h/L的25%范围内。观察到2例3级不良事件(药物性肝损伤和皮肤色素沉着)可能与氯法齐明相关,3例参与者出现5次QTcF延长。
要点
- 50mg氯法齐明片剂按修订每日一次体重分层给药可达成人暴露目标的25%范围内。
- 需警惕药物性肝损伤、皮肤色素沉着及QTcF延长,建议ECG和实验室监测。
- 广泛采用前需进一步评估。
核心结论
- 修订的每日一次50mg氯法齐明片剂给药方案达到了预设的暴露目标。
- 临床重要不良事件支持在ECG和实验室监测下谨慎使用,广泛采用前需进一步评估。
研究设计与样本
- 纳入<18岁、体重<30kg、接受含氯法齐明MDR/RR-TB治疗的儿童。
- 在基线、第2周和第12周进行稀疏和半密集药代动力学采样。
- 共纳入12例儿童,中位年龄2.8岁(范围0.6-8.2)。
主要发现
- 中位预测稳态周AUC为106 mg·h/L(范围76.9-274),在成人目标111.79 mg·h/L的25%范围内。
- 观察到2例3级不良事件(药物性肝损伤和皮肤色素沉着)可能与氯法齐明相关,无其他氯法齐明相关严重不良事件。
- QTcF间期通常随氯法齐明浓度每增加1 µg/L而增加0.042 ms;3例参与者出现5次QTcF延长(>460-480 ms)。
关键数值与推荐
- 成人目标稳态周AUC为111.79 mg·h/L。
- QTcF延长定义为>460-480 ms。
临床怎么用
- 儿童MDR/RR-TB使用氯法齐明时可采用50mg片剂按修订每日一次体重分层给药。
- 治疗期间应进行ECG和实验室监测,警惕肝损伤、皮肤色素沉着和QTcF延长。
局限性
- 样本量小(12例),年龄范围窄(0.6-8.2岁)。
- 广泛采用前需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clofazimine is commonly included in multidrug regimens for children with multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB), but accurate pediatric dosing has been limited by 100-mg soft-gel capsules that cannot be reliably divided. We evaluated the exposure and safety of a novel 50-mg clofazimine tablet using revised once-daily weight-banded dosing informed by a previous study (Clofazimine PK1). METHODS: Children <18 years weighing <30 kg receiving MDR/RR-TB treatment, including clofazimine, were enrolled. Sparse and semi-intensive pharmacokinetic sampling was completed at baseline and at weeks 2 and 12. Model-predicted weekly steady-state area-under-the-curve (wAUCss) was compared with an adult target of 111.79 mg·h/L. Safety monitoring included clinical, laboratory, and electrocardiogram (ECG) monitoring. RESULTS: Twelve children were included (median age 2.8 years; range 0.6-8.2). Median predicted wAUCss was 106 mg·h/L (range 76.9-274), within 25% of target. Two grade 3 adverse events (drug-induced liver injury and skin hyperpigmentation) possibly related to clofazimine, but no other clofazimine-related serious adverse events, were observed, The Fridericia corrected QT (QTcF) interval typically increased with 0.042 ms per1-µg/L increase in clofazimine concentration; five QTcF prolongations (>460-480 ms) occurred in three participants. CONCLUSIONS: The revised once-daily dosing with the 50-mg clofazimine tablet achieved the predefined exposure target. Clinically important adverse events support cautious use with ECG and laboratory monitoring and further evaluation before broad adoption. CLINICAL TRIALS REGISTRATION: South African National Clinical Trials Register (https://sanctr.samrc.ac.za/; DOH-27-0620-6415).
引用
- Nortier E, Boczar MM, Hughes JA, et al. Pharmacokinetics and Safety of a Novel Clofazimine Formulation and Dosing Strategy in Children With Rifampicin-resistant Tuberculosis. J Infect Dis. 2026. PMID: 42590848. doi:10.1093/infdis/jiag381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。